1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Target Disease
4.2.2 Introduction of New and Innovative Technologies and Drugs
4.2.3 Increased Government Funding & Awareness Programs
4.3 Market Restraints
4.3.1 High Failure Rates of Drugs at Approval Stages
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Indications
5.1.1 Lewy Body Dementia
5.1.2 Parkinsons Disease Dementia
5.1.3 Alzheimer's Disease
5.1.4 Vascular Dementia
5.1.5 Others
5.2 By Drug Class
5.2.1 MAO Inhibitors
5.2.2 Glutamate Inhibitors
5.2.3 Cholinesterase Inhibitors
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Apotex Inc
6.1.2 AstraZeneca
6.1.3 Aurobindo Pharma
6.1.4 Eisai Co., Ltd
6.1.5 Eli Lilly and Company
6.1.6 Johnson and Johnson
6.1.7 Pfizer, Inc.
6.1.8 Teva Pharmaceuticals
6.1.9 Zydus Cadila

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Apotex Inc
- AstraZeneca
- Aurobindo Pharma
- Eisai Co., Ltd
- Eli Lilly and Company
- Johnson and Johnson
- Pfizer, Inc.
- Teva Pharmaceuticals
- Zydus Cadila